•
Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a multi-region, multi-center clinical study for its innovative fusion protein, HCB101. The non-blind, dose exploration first-in-human trial will be conducted in the US and Taiwan, focusing on assessing the safety, tolerability, pharmacokinetics, and preliminary clinical anti-tumor…
•
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership with Swiss company Sonova, marking a Sino-Swiss collaboration aimed at enhancing the introduction and implementation of innovative hearing health solutions in China. The partnership focuses on jointly promoting the introduction of cutting-edge hearing aids and…
•
Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions in China, has reportedly raised RMB 236 million (USD 34.3 million) in a Series B financing round. The round was led by 3H Health Investment, with participation from Vertex Ventures and ZhenCheng Capital. The funds…
•
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for the VEGFR inhibitor Elunate (fruquintinib) in China. The filing focuses on the use of Elunate in combination with paclitaxel as a second-line treatment for advanced gastric or gastroesophageal…
•
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) in China for its ophthalmology gene therapy, HG004. This gene replacement therapy drug utilizes a recombinant non-adeno-associated virus serotype 2 (non-AAV2) vector to deliver a functional human RPE65 gene…
•
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the Phase I clinical study for its C-CAR031 at the American Association for Cancer Research (AACR) annual meeting 2023. The open Phase I study was designed to assess the safety and tolerability of C-CAR031, featuring a…
•
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording RMB 1.031 billion (USD 149.9 million) in revenue, marking a 76.02% year-on-year (YOY) decrease, and reporting RMB 187 million (USD 27.19 million) in losses compared to RMB 3 billion (USD 436 million) in gross profits…
•
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing hundreds of millions of renminbi. The round was led by a consortium of investors including GDD Industry Fund, Guangzhou Xinxing Industry Development Fund, Yuegang Capital, Sanmei Investment, and Guangzhou Guoju Venture Capital, along with an…
•
Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic drugs, has announced the completion of a Series A financing round worth RMB 100 million (USD 14.5 million). The investment was led by Jiangsu Tech Industry Investment Co., Ltd. Company Background and ServicesFounded in 2019,…
•
Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring semiconductor laser therapy equipment, the SinoLITT System, and disposable laser fiber kit have been approved by the National Medical Products Administration (NMPA) for use in laser treatment of local lesions in patients with drug-resistant epilepsy,…
•
German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published a study demonstrating the application of molecular dynamics (MD) simulations to guide small-molecule crystallization experiments. This innovative approach aims to achieve crystal shapes that facilitate crystallography data collection throughout the drug development process. Case Study:…
•
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Sino-US multi-center Phase I/II study. The study will assess the safety, efficacy, and tolerability of its gene therapy NFS-02 (rAAV2-ND1) for ND1…
•
Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly raised nearly RMB 200 million (USD 29.1 million) in a Series C+ financing round. The round was led by Loyal Valley Capital, with participation from Greenwoods Asset, highlighting the strong investor confidence in Core Medtech’s…
•
Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it has received marketing approval from Health Canada for its generic version of Roche’s Cytovene-IV (ganciclovir). This development marks a significant step for the company as it expands its international footprint in the generic drugs market.…
•
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more than RMB 200 million (USD 29.1 million) in a Series B financing round. This significant investment, led by CCB Trust, will fuel the company’s efforts in advancing stem-cell drugs for a variety of diseases and…
•
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is…
•
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative bivalent COVID-19 mRNA vaccine. This development signifies a significant step forward in the company’s efforts to combat the evolving SARS-CoV-2 virus. Preclinical Study…
•
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed in a Phase Ib clinical study for its small-molecule aurora A kinase (AURKA) inhibitor, VIC-1911. This trial marks a significant step in the development of the drug, which is being investigated for its potential in…
•
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for the year 2022, showcasing a significant increase in revenues. The company recorded RMB 6.139 billion (USD 920 million) in revenues, marking a 26.4% year-on-year (YOY) growth. Revenue Breakdown and R&D InvestmentRevenues from the innovative medicine…
•
China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter of 2023, showing a robust increase in revenues. As of March 31, 2023, the company reported revenues of RMB 995.7 million (USD 144.9 million), marking a 97.2% year-on-year (YOY) growth. Sales Performance of Key ProductsHenlius’s…